1. Home
  2. NTLA vs MLAB Comparison

NTLA vs MLAB Comparison

Compare NTLA & MLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • MLAB
  • Stock Information
  • Founded
  • NTLA 2014
  • MLAB 1982
  • Country
  • NTLA United States
  • MLAB United States
  • Employees
  • NTLA N/A
  • MLAB N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • MLAB Industrial Machinery/Components
  • Sector
  • NTLA Health Care
  • MLAB Industrials
  • Exchange
  • NTLA Nasdaq
  • MLAB Nasdaq
  • Market Cap
  • NTLA 710.1M
  • MLAB 680.0M
  • IPO Year
  • NTLA 2016
  • MLAB N/A
  • Fundamental
  • Price
  • NTLA $6.87
  • MLAB $100.62
  • Analyst Decision
  • NTLA Buy
  • MLAB Hold
  • Analyst Count
  • NTLA 20
  • MLAB 2
  • Target Price
  • NTLA $38.40
  • MLAB $130.00
  • AVG Volume (30 Days)
  • NTLA 5.0M
  • MLAB 40.8K
  • Earning Date
  • NTLA 05-08-2025
  • MLAB 05-28-2025
  • Dividend Yield
  • NTLA N/A
  • MLAB 0.64%
  • EPS Growth
  • NTLA N/A
  • MLAB N/A
  • EPS
  • NTLA N/A
  • MLAB N/A
  • Revenue
  • NTLA $45,569,000.00
  • MLAB $240,978,000.00
  • Revenue This Year
  • NTLA N/A
  • MLAB $6.63
  • Revenue Next Year
  • NTLA N/A
  • MLAB $5.61
  • P/E Ratio
  • NTLA N/A
  • MLAB N/A
  • Revenue Growth
  • NTLA N/A
  • MLAB 11.47
  • 52 Week Low
  • NTLA $5.90
  • MLAB $83.68
  • 52 Week High
  • NTLA $28.18
  • MLAB $155.12
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 38.33
  • MLAB 32.32
  • Support Level
  • NTLA $8.93
  • MLAB $98.06
  • Resistance Level
  • NTLA $9.79
  • MLAB $115.35
  • Average True Range (ATR)
  • NTLA 0.58
  • MLAB 5.56
  • MACD
  • NTLA -0.15
  • MLAB -2.02
  • Stochastic Oscillator
  • NTLA 1.35
  • MLAB 7.72

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About MLAB Mesa Laboratories Inc.

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Share on Social Networks: